Radiation enhancer
enhances ----------------------------- Allos Therapeutics of Denver
announced that 87% of 30 evaluable patients with non-small-cell lung cancer
had a complete or partial response to RSR13, which enhances radiation given
after chemotherapy. This compares with historical response rates of about
60% to chemotherapy and radiation alone. The company is also investigating
the agent for brain metastases and glioblastoma multiforme.
